Improved Myeloma Diagnosis Based on Blood Count Components
By LabMedica International staff writers Posted on 27 Aug 2018 |
Image: A photomicrograph of a myeloma colored with hematoxylin and eosin stain (Photo courtesy of Wikipedia Commons).
A team of British researchers has found which blood tests could be useful for suggesting or excluding a diagnosis of myeloma.
Multiple myeloma is a hematological cancer characterized by numerous non-specific symptoms leading to diagnostic delay in a large proportion of patients. Symptoms can occur up to two years before diagnosis in other cancers, but little is known about the timing of symptoms and abnormal blood test results before diagnosis in myeloma.
Investigators at the University of Exeter (United Kingdom) and the University of Oxford (United Kingdom) sought to identify the best inflammatory markers for initial investigation of possible myeloma, useful blood tests for ruling out symptomatic myeloma, and how to distinguish early and late features of the disease.
For this study, they analyzed symptom prevalence and blood tests up to five years before diagnosis in 2703 cases and 12,157 matched controls. Likelihood ratios (LR) were used to classify tests or their combinations as useful rule-in or rule-out tests.
Results suggested that the best inflammatory markers to supplement symptoms of myeloma were plasma viscosity (PV) and erythrocyte sedimentation rate (ESR), while C-reactive protein (CRP) was unhelpful. In addition, the combination of normal hemoglobin and PV could be used to rule out the disease on patients currently being tested in primary care. The results further demonstrated that the full blood count components and especially low hemoglobin were among the earliest presentations of the disease, which may allow the diagnosis to be expedited.
Senior author Dr. William Hamilton, professor of primary care diagnostics at the University of Exeter, said, "Ordinarily a GP will see a patient with myeloma every five years - and early diagnosis matters. More timely treatment could significantly improve survival rates for this disease. We report a simple way a GP can check patients presenting symptoms such as back, rib, and chest pain, or recurrent chest infections, and determine whether they have myeloma or not."
The study was published in the August 13, 2018, online edition of the British Journal of General Practice.
Related Links:
University of Exeter
University of Oxford
Multiple myeloma is a hematological cancer characterized by numerous non-specific symptoms leading to diagnostic delay in a large proportion of patients. Symptoms can occur up to two years before diagnosis in other cancers, but little is known about the timing of symptoms and abnormal blood test results before diagnosis in myeloma.
Investigators at the University of Exeter (United Kingdom) and the University of Oxford (United Kingdom) sought to identify the best inflammatory markers for initial investigation of possible myeloma, useful blood tests for ruling out symptomatic myeloma, and how to distinguish early and late features of the disease.
For this study, they analyzed symptom prevalence and blood tests up to five years before diagnosis in 2703 cases and 12,157 matched controls. Likelihood ratios (LR) were used to classify tests or their combinations as useful rule-in or rule-out tests.
Results suggested that the best inflammatory markers to supplement symptoms of myeloma were plasma viscosity (PV) and erythrocyte sedimentation rate (ESR), while C-reactive protein (CRP) was unhelpful. In addition, the combination of normal hemoglobin and PV could be used to rule out the disease on patients currently being tested in primary care. The results further demonstrated that the full blood count components and especially low hemoglobin were among the earliest presentations of the disease, which may allow the diagnosis to be expedited.
Senior author Dr. William Hamilton, professor of primary care diagnostics at the University of Exeter, said, "Ordinarily a GP will see a patient with myeloma every five years - and early diagnosis matters. More timely treatment could significantly improve survival rates for this disease. We report a simple way a GP can check patients presenting symptoms such as back, rib, and chest pain, or recurrent chest infections, and determine whether they have myeloma or not."
The study was published in the August 13, 2018, online edition of the British Journal of General Practice.
Related Links:
University of Exeter
University of Oxford
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans